Merck reports Q3 earnings on Oct. 29 with KEYTRUDA's 2028 patent clock ticking louder, and whether LIPFENDRA, QLEX, and ...
The INTerpath-001 trial randomized 1,137 patients with resected stage IIB to IV melanoma to Keytruda alone or Keytruda plus ...
Tampa Free Press on MSN
On high alert: Uganda imposes strict Ebola quarantine after airport transit cases emerge
Ugandan citizens returning from the Democratic Republic of Congo must undergo a mandatory 21-day quarantine as authorities ...
Asianet Newsable on MSN
Stocktwits Pharma Pulse: Big pharma earnings, cancer updates and 2 FDA deadlines — the week’s biotech watchlist
Lilly and Merck report earnings on Thursday, followed by AbbVie on Friday.
After 100 years, there's finally an effective cancer vaccine. Now comes the push to get them to work in more tumor types.
As assessed by blinded independent central review (BICR), the objective response rate was 50.2% and 47.3% in the two groups, ...
11h
Cancer vaccine significantly reduces chance of melanoma patients’ tumours returning, results show
Adding vaccine to standard post-surgery treatment reduced risk of melanoma returning by 42% two years after surgery ...
After an overall miss, a subgroup showed a 2+ month survival gain; Pfizer is testing sigvotatug vedotin with Merck's Keytruda ...
A Roche Holding AG drug billed as a potential blockbuster helped patients with a form of lung cancer that had spread live ...
Lilly’s olomorasib showed promising lung cancer trial results, boosting its KRAS G12C treatment outlook ahead of key Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results